Mark W. Lundy, PhD

Dr. Lundy is a skilled histopathologist who has studied the biochemical and pharmacological mechanism of bone metabolism for over 35 years.  He has extensive in vivo pharmacology expertise and a particularly strong knowledge of drug pharmacology on the skeleton. He has helped develop potent bone anabolic agents, and was involved in understanding the distribution and effects of the bisphosphonate drug class. He was a part of the team that first studied fluorescent bisphosphonates in vivo and with his microscopy collaborators such as Prof. Alan Boyde, Dr. Fraser Coxon and Prof. Matt Allen, demonstrated differential distribution of various bisphosphonates in vivo.

Dr. Lundy continues to study new medical uses and mechanisms of bisphosphonates and continues to be integral in planning new studies and applications of fluorescent bisphosphonates. He has a particular interest in the development of new diagnostics that identify sites of increased bone turnover, specifically including sites of increased bone resorption. These markers are useful in identifying and following response to therapy for bone diseases, such as osteoporosis, arthritis, and cancers affecting bone. Dr. Lundy has published extensively and is currently the Director of Biology at BioVinc and an Adjunct Associate Professor at the Indiana University School of Medicine.

Phone: 1-513-313-3687